Recombinant PD-L1 (CD274) Protein

Sign InRegister

English

PD-L1 Overview

Molecule Name

Programmed death-ligand 1

Synonyms

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

Drug Development Progress

Drugs in Clinical Trials172

Approved Drugs12

Highest Development StageApproved

Target Synonym

HPD-L1，Programmed Cell Death 1 Ligand 1，PDCD1L1，B7H1，PDL1，Programmed Death Ligand 1，B7-H1，B7-H，B7-H1 Antigen，CD274，B7 homolog 1，PDCD1 ligand 1，PD-L1，PDCD1LG1，CD274 Molecule，CD274 Antigen

Background

Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

PD-L1 Product List

Molecule	Cat. No.	Product Name	Species	Host	Purity	Activity	Size&Price
PD-L1	HOTAIDD‑Ready PD1-H5229	Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)	Human	HEK293	MSMALSSDS-PAGE	ELISASPRBLI	$355.00 100ug
PD-L1	HOTAvitag PDL-H82F2	Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISA	$360.00 25ug
PD-L1	HOTAvitag PDL-H82E4	Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISA	$360.00 25ug
PD-L1	HOTAIDD‑Ready PD1-H5258	Human PD-L1 / B7-H1 Protein, Fc Tag, low endotoxin (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISABLIFlowCELL BASE	$330.00 100ug
PD-L1	HOTAvitag PD1-H82E5	Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISA	$415.00 25ug
PD-L1	AIDD‑Ready PD1-C5253	Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag (MALS & BLI verified)	Cynomolgus / Rhesus macaque	HEK293	MALSSDS-PAGE	ELISABLI	$360.00 100ug
PD-L1	AIDD‑Ready PD1-C5255	Feline PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)	Feline	HEK293	MALSSDS-PAGE	ELISASPR	$360.00 100ug
PD-L1	AIDD‑Ready PD1-C52H3	Canine PD-L1 / B7-H1 Protein, Fc Tag, low endotoxin	Canine	HEK293	SDS-PAGE	BLI	$360.00 100ug
PD-L1	AIDD‑Ready PD1-C52H4	Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag, low endotoxin (MALS verified)	Cynomolgus / Rhesus macaque	HEK293	MALSSDS-PAGE	ELISASPRBLI	$360.00 100ug
PD-L1	AvitagAIDD‑Ready PD1-C82F3	Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)	Cynomolgus / Rhesus macaque	HEK293	MALSSDS-PAGE	ELISASPR	$360.00 25ug

PD-L1 >

HotAIDD‑Ready

Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)

Cat. No. PD1-H5229

Species

Human

Host

HEK293

Purity

MSMALSSDS-PAGE

Activity

ELISASPRBLI

$355.00

PD-L1 >

HotAvitag

Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)

Cat. No. PDL-H82F2

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISA

$360.00

PD-L1 >

HotAvitag

Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)

Cat. No. PDL-H82E4

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISA

$360.00

PD-L1 >

HotAIDD‑Ready

Human PD-L1 / B7-H1 Protein, Fc Tag, low endotoxin (MALS verified)

Cat. No. PD1-H5258

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISABLIFlowCELL BASE

$330.00

PD-L1 >

HotAvitag

Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (MALS verified)

Cat. No. PD1-H82E5

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISA

$415.00

PD-L1 >

AIDD‑Ready

Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag (MALS & BLI verified)

Cat. No. PD1-C5253

Species

Cynomolgus / Rhesus macaque

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISABLI

$360.00

PD-L1 >

AIDD‑Ready

Feline PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)

Cat. No. PD1-C5255

Species

Feline

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISASPR

$360.00

PD-L1 >

AIDD‑Ready

Canine PD-L1 / B7-H1 Protein, Fc Tag, low endotoxin

Cat. No. PD1-C52H3

Species

Canine

Host

HEK293

Purity

SDS-PAGE

Activity

BLI

$360.00

PD-L1 >

AIDD‑Ready

Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag, low endotoxin (MALS verified)

Cat. No. PD1-C52H4

Species

Cynomolgus / Rhesus macaque

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISASPRBLI

$360.00

PD-L1 >

AvitagAIDD‑Ready

Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)

Cat. No. PD1-C82F3

Species

Cynomolgus / Rhesus macaque

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISASPR

$360.00

You Have Viewed 1-10 Of 27 Results

No Data

FAQ

What critical biophysical quality attributes make ACROBiosystems' anti-idiotypic antibodies highly reliable across multi-year clinical campaigns?

Multi-year clinical trials require reagents with unwavering batch consistency and minimal risk of assay drift. ACROBiosystems’ anti-idiotypic antibody portfolio features: Picomolar Affinity (KD): Characterized via Surface Plasmon Resonance (SPR), reaching picomolar binding strength (e.g., clone ADB-Y19 binds Adalimumab with an affinity constant of 1.36 pM). SEC-MALS Verification: Select clones undergo Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS) to confirm purity and a defined monomeric molecular weight. High Thermal & Freeze-Thaw Stability: Validated through accelerated 37°C stress tests and repeated freeze-thaw cycles without activity loss.

What critical biophysical quality attributes make ACROBiosystems' anti-idiotypic antibodies highly reliable across multi-year clinical campaigns?

How do cell-based reporter bioassays and stable overexpression cell lines complement cell-free assays during anti-PD-L1 antibody screening?

While recombinant proteins provide precise cell-free kinetic parameters (SPR/ELISA), cell-based models confirm functional antibody activity in native membrane geometry. ACROBiosystems provides PD-L1 Overexpression Stable Cell Lines and Cell-Based Reporter Bioassays: Overexpression Cell Lines: Display full-length human PD-L1 with authentic post-translational modifications, supporting flow cytometry (FACS) binding and competition studies. Reporter Bioassays: Quantify the functional blockade of the PD-1/PD-L1 signaling axis by measuring NFAT or NF-κB promoter-driven luciferase activity upon co-culture, providing reproducible bioactivity data for lot release and characterization.

What research tools are available for PD-L1 studies?

PD-L1 research often requires different tools depending on the application. Recombinant proteins, assay kits, cell lines, and antibodies can be used across different research workflows. ACROBiosystems provides these PD-L1 research tools in multiple species and formats to support binding studies, inhibitor screening, assay development, and cell-based research.

When are labeled PD-L1 proteins used in cell-based assays?

Labeled PD-L1 proteins are commonly used to evaluate binding to PD-1-expressing cells in flow cytometry and other cell-based assays. They enable direct detection of target engagement while simplifying assay workflows by reducing the need for additional detection reagents.

How are PD-1/PD-L1 binding interactions commonly analyzed?

PD-1/PD-L1 binding interactions are commonly analyzed using biochemical and cell-based assays. Recombinant PD-L1 proteins are widely used in SPR, BLI, and ELISA to characterize receptor–ligand binding, while cell-based assays help evaluate target engagement in a more physiologically relevant context. The appropriate method depends on the experimental objective and assay platform.

What is the difference between His-tagged, Fc-tagged, and biotinylated PD-L1 proteins?

Different PD-L1 protein formats are designed for different experimental needs. His-tagged proteins are commonly used for purification and general binding assays. Fc-tagged proteins facilitate Fc-mediated capture or detection and may improve protein stability. Biotinylated PD-L1 proteins enable site-specific immobilization through streptavidin, making them well suited for applications such as SPR, BLI, ELISA, and biopanning.

What is recombinant PD-L1 protein used for?

Recombinant PD-L1 proteins are widely used to study the PD-1/PD-L1 immune checkpoint pathway. They support applications such as receptor–ligand interaction analysis, antibody characterization, inhibitor screening, assay development, and cell-based binding studies. Selecting the appropriate species and protein format helps generate reliable and reproducible experimental results.

Asset Licensing Opportunity

Resources

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Bintrafusp alfa	M-7824; GSK-4045154; MSB-0011359C	Phase 3 Clinical	Merck Serono	Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop	Details
Erfonrilimab	KN-046	Phase 3 Clinical	Jiangsu Alphamab Biopharmaceuticals Co Ltd	Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms	Details
HLX-43	HLX-43; HLX43	Phase 3 Clinical	Shanghai Henlius Biotech Inc	Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
LB-1410	LB-1410	Phase 3 Clinical	L&L Biopharma Co Ltd	Lymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms	Details
SGN-PDL1V	SGN-PDL1V; PF-08046054	Phase 3 Clinical	Seagen Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
SHS-006(Nanjing Sanhome Pharmaceutical)	SHS-006; SH-006; SH006	Phase 3 Clinical	Nanjing Sanhome Pharmaceutical Co Ltd	Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours	Details
CA-170	CA-170; AUPM-170	Phase 3 Clinical	Aurigene	Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours	Details
Sotiburafusp alfa	HB0025; HB-0025	Phase 3 Clinical	HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
HL-301	HL-301	Phase 3 Clinical	Hanmi Pharmaceutical Co Ltd	Acute Bronchitis; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis	Details
Pumitamig	PM-8002; BMS-986545; PM8002; BNT-327	Phase 3 Clinical		Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
FAZ-053	FAZ-053; LAE-005; LAE005	Phase 2 Clinical	Novartis Pharma Ag	Chordoma; Sarcoma, Alveolar Soft Part; Solid tumours; Triple Negative Breast Neoplasms	Details
MAX-10181	MAX-1; MAX-10181; MX-10181	Phase 2 Clinical	MaxiNovel Pharmaceuticals Co Ltd	Glioblastoma; Glioma; Neoplasms; Solid tumours	Details
89Zr-DFO-Atezolizumab	89Zr-DFO-Atezolizumab	Phase 2 Clinical	University of Texas Southwestern Medical Center	Carcinoma, Renal Cell; Diagnostic agents; Lymphoma, B-Cell	Details
PD-L1 t-haNK cell therapy		Phase 2 Clinical	Nantkwest Inc	Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Details
RC-98	RC-98; RC98; RC98-ADC	Phase 2 Clinical		Solid tumours; Stomach Neoplasms	Details
Durvalumab/Gefitinib		Phase 2 Clinical	Medimmune	Carcinoma, Non-Small-Cell Lung	Details
Vudalimab	XmAb-717; XmAb-20717; XmAb 717	Phase 2 Clinical	Xencor Inc	Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms	Details
Cadapersen	RG-6084; RO-7191863	Phase 2 Clinical	F. Hoffmann-La Roche Ltd	Hepatitis B; Hepatitis B, Chronic	Details
BMS-936559	MDX-1105; BMS-936559	Phase 2 Clinical	Bristol-Myers Squibb Company	Colonic Neoplasms; Colorectal Neoplasms; HIV Infections; Hodgkin Disease; Leukemia, Myelogenous, Chronic; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Rectal Neoplasms; Sepsis; Shock, Septic; Small Cell Lung Carcinoma	Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital)		Phase 2 Clinical	Changhai Hospital of Navy Medical University	Pancreatic Neoplasms	Details
PM-8001	6MW3111; PM-8001	Phase 2 Clinical		Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Solid tumours	Details
Betifisolimab	MSB-2311	Phase 2 Clinical	Suzhou Transcenta Therapeutics Co Ltd	Solid tumours	Details
Evixapodlin	GS-4224; OX-4224	Phase 2 Clinical	Gilead Sciences Inc	Carcinoma, Non-Small-Cell Lung; Solid tumours	Details
89Zr-durvalumab		Phase 2 Clinical	Radboud University Nijmegen	Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms	Details
Danburstotug	STI-3031; STI-A1015; IMC-001	Phase 2 Clinical	Sorrento Therapeutics Inc	Biliary Tract Neoplasms; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms; Solid tumours	Details
Type 1 diabetes stem cell gene therapy (Altheia Science)		Phase 2 Clinical	Altheia Science Srl	Diabetes Mellitus, Type 1	Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology)	LP-002	Phase 2 Clinical	Taizhou Houde Aoke Technology Co Ltd	Carcinoma, Squamous Cell; Digestive System Neoplasms; Melanoma; Primary mediastinal B cell lymphoma; Small Cell Lung Carcinoma; Solid tumours	Details
AP-203	AP-203; AP203	Phase 2 Clinical	AP Biosciences Inc	Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
HB-0036	HB-0036	Phase 2 Clinical	HuaBo Biopharm Co Ltd	Carcinoma, Non-Small-Cell Lung; Solid tumours	Details
SKB-103	SKB103; SKB-103	Phase 2 Clinical	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Solid tumours	Details
[18F]AlF-NOTA-PCP2	18F-AlF-NOTA-PCP2	Phase 2 Clinical	Shandong First Medical University	Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Squamous Cell Carcinoma of Head and Neck	Details
HY-05350	HY-0005; HY-05350	Phase 2 Clinical	Sichuan Huiyu Seacross Pharma Technology Ltd	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
IBI-3014	IBI3014; IBI-3014	Phase 2 Clinical		Solid tumours	Details
DB-1419	DB-1419	Phase 2 Clinical	Duality Biologics (Suzhou) Co Ltd	Solid tumours	Details
CVL006	CVL006; B006	Phase 2 Clinical	Convalife (Shanghai) Co Ltd	Neoplasms; Solid tumours	Details
SOA-101	SOA-101; SOA101	Phase 2 Clinical	Shine-On BioMedical Co Ltd	Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Mouth Neoplasms; Ovarian Neoplasms; Solid tumours	Details
JSKN-033	JSKN033; JSKN-033; JSKN-003/Envafolimab	Phase 2 Clinical	Jiangsu Alphamab Biopharmaceuticals Co Ltd	Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms	Details
SPX-303	SPX-303	Phase 2 Clinical	SparX Biopharmaceutical Corp	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
MAX-80391	MAX-80391; MAX-8	Phase 2 Clinical	MaxiNovel Pharmaceuticals Co Ltd	Solid tumours	Details
PRS-344	PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012	Phase 2 Clinical	Pieris Pharmaceuticals Inc	Solid tumours	Details
Pacmilimab	CX-072	Phase 2 Clinical	Cytomx Therapeutics Inc	Breast Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
BPB-101	BPB-101	Phase 2 Clinical	Betta Pharmaceuticals Co Ltd	Solid tumours	Details
LB-101 (Centessa Pharmaceuticals)	LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody	Phase 2 Clinical	Centessa Pharmaceuticals Plc	Solid tumours	Details
HK-010	HK-010; HK010	Phase 2 Clinical	Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd	Neoplasms; Solid tumours	Details
AB-001 (Agastiya Biotech)	AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech)	Phase 2 Clinical	Agastiya Biotech LLC	Neoplasms	Details
6MW-3511	6MW-3511	Phase 2 Clinical	Mabwell (Shanghai) Bioscience Co Ltd	Neoplasms; Solid tumours	Details
18F-BMS-986229	18F-BMS-986229; [18F]BMS-986229	Phase 2 Clinical	Bristol-Myers Squibb International Corp, PeptiDream Inc	Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Stomach Neoplasms	Details
AP-505	AP-505; B1962; AP505	Phase 2 Clinical	AP Biosciences Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
Emfizatamab	GNC-038	Phase 2 Clinical	Sichuan Baili Pharmaceutical Co Ltd, SystImmune	Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours	Details
99mTc-NM-01	99mTc-NM-01	Phase 2 Clinical	Nanomab Technology Ltd	Carcinoma, Non-Small-Cell Lung	Details
HB-0028	HB-0028	Phase 2 Clinical	HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd	Solid tumours; Uterine Cervical Neoplasms	Details
PM-1022	PM-1022	Phase 2 Clinical		Neoplasms	Details
DR-30206	DR-30206	Phase 2 Clinical	Zhejiang Doer Biologics Corp	Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
706-3SBio	SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody	Phase 2 Clinical	3sbio Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours	Details
BCD-106	BCD-106	Phase 2 Clinical	BIOCAD JSC	Solid tumours	Details
BAT-7104	BAT-7104	Phase 2 Clinical	Bio-Thera Solutions Ltd	Neoplasms; Solid tumours	Details
Opamtistomig	LBL-024; LBL024	Phase 2 Clinical	Nanjing Leadsbiolabs Co Ltd	Carcinoma, Neuroendocrine; Melanoma; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
IBC-0966	IBC-0966	Phase 2 Clinical		Neoplasms	Details
QLF31907	QLF31907; QLF-31907	Phase 2 Clinical	Qilu Pharmaceutical Co Ltd	Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Solid tumours	Details
INCB-099280	INCB-099280; INCB-99280	Phase 2 Clinical	Incyte Corp Ltd	Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms	Details
FH-2001	FH-2001	Phase 2 Clinical		Solid tumours	Details
Nebratamig	GNC-035	Phase 2 Clinical	Sichuan Baili Pharmaceutical Co Ltd	Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours	Details
Carrizumab		Phase 2 Clinical	Jiangsu Hengrui Medicine Co Ltd	Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms	Details
Recombinant anti-PD-L1/TGF-β bispecific antibody	Y101D; Y-101D	Phase 2 Clinical	Wuhan Yzy Biopharma Co Ltd	Carcinoma, Hepatocellular; Pancreatic Neoplasms; Solid tumours	Details
6MW-3211	6MW3211; 6MW-3211	Phase 2 Clinical	Mabwell (Shanghai) Bioscience Co Ltd	Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms	Details
Q-1802	Q-1802	Phase 2 Clinical	Qure Biotechnology (Shanghai) Co Ltd	Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours	Details
HLX-301	HLX-301	Phase 2 Clinical		Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital)		Phase 2 Clinical	Shanghai Zhongshan Hospital	Cholangiocarcinoma	Details
Palverafusp alfa	IMM-2510; SYN-2510; AXN-2510	Phase 2 Clinical		Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms	Details
PM-1003	PM1003	Phase 2 Clinical		Solid tumours	Details
PM-8003	PM8003	Phase 2 Clinical		Solid tumours	Details
ABSK-043	ABSK043	Phase 2 Clinical	ABbisko Therapeutics Co Ltd	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Sarcoma; Solid tumours	Details
Lesabelimab	BC-003; ADG-104	Phase 2 Clinical	Adagene (Suzhou) Ltd, Baifan Biotechnology (Shanghai) Co Ltd, Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd	Carcinoma, Renal Cell; Neoplasms; Penile Neoplasms; Urinary Bladder Neoplasms	Details
Emdifen		Phase 1 Clinical	Chinese Academy Of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co Ltd	Solid tumours	Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)	Z-CTLs	Phase 1 Clinical	Hunan Zhaotai Yongren Biotech Co Ltd	Carcinoma, Non-Small-Cell Lung	Details
Lodapolimab	LY-3300054	Phase 1 Clinical	Eli Lilly And Company	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Microsatellite instability-high cancer; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms	Details
SL-279252	TAK-252; SL-279252	Phase 1 Clinical	Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd	Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
LOR-S03	CDX-527	Phase 1 Clinical	Celldex Therapeutics	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms	Details
MCLA-145	MCLA-145	Phase 1 Clinical	Incyte Corp, Merus Nv	Lymphoma, B-Cell; Neoplasms; Solid tumours	Details
INCB-086550	INCB-086550; INCB-86550	Phase 1 Clinical	Incyte Corp	Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours	Details
Opucolimab	HLX-20	Phase 1 Clinical		Neoplasms; Solid tumours	Details
IMMH-010	IMMH-010	Phase 1 Clinical	Tianjin Chase Sun Pharmaceutical Co Ltd	Neoplasms; Solid tumours	Details
Simridarlimab	IBI-322; IBI322	Phase 1 Clinical		Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours	Details
dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University)		Phase 1 Clinical	Sichuan University	Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms	Details
anti-PD-L1 CSR T-cell therapy (Marino Biotechnology)		Phase 1 Clinical	Beijing Marino Biotechnology Co Ltd	Glioblastoma; Neoplasms	Details
anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine)		Phase 1 Clinical	Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd	Hormone-Resistant Prostate Neoplasms	Details
AB-101 (Arbutus Biopharma)	AB-101 (Arbutus Biopharma)	Phase 1 Clinical	Arbutus Biopharma Corp	Hepatitis B; Hepatitis B, Chronic	Details
SIM-0237	SIM-0237; SIM-237	Phase 1 Clinical	Simcere Pharmaceutical Group Ltd	Solid tumours; Urinary Bladder Neoplasms	Details
LP-008	LP-008	Phase 1 Clinical	Lepu Biopharma Co Ltd	Solid tumours	Details
AN-8025	AN-8025	Phase 1 Clinical	Hangzhou Adlai Nortye Biopharma Co Ltd	Solid tumours	Details
EMB-09	EMB-09	Phase 1 Clinical	Shanghai Epimab Biotherapeutics, Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
CYTO-102	CYTO-NK-102; CYTO-102; COH06	Phase 1 Clinical	CytoImmune Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms	Details
TS-1905	TS-1905; LY-01019; BA-1201	Phase 1 Clinical	Shandong Boan Biotechnology Co Ltd	Solid tumours	Details
BH-3120	BH-3120	Phase 1 Clinical	Hanmi Pharmaceutical Co Ltd	Solid tumours	Details
Xirestomig	ATG-101; ATG101; YN051	Phase 1 Clinical	The Origin Cell Technology Group Co Ltd	Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours	Details
QL-301	QL-301	Phase 1 Clinical	Qlsf Biotherapeutics Inc	Neoplasms	Details
HLX-37	HLX37; HLX-37	Phase 1 Clinical	Shanghai Henlius Biotech Inc	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Triple Negative Breast Neoplasms	Details
Q-1801	Q-1801; Q 1801	Phase 1 Clinical	Qure Biotechnology (Shanghai) Co Ltd	Solid tumours	Details
PEC-QT	PEC-QT; VCTX-210	Phase 1 Clinical	Crispr Therapeutics Ag, Viacyte Inc	Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endocrine System Diseases; Glucose Metabolism Disorders; Immune System Diseases; Metabolic Diseases	Details
IMGS-001	IMGS-001	Phase 1 Clinical	The University Of Texas MD Anderson Cancer Center	Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
ABL-501	ABL-501	Phase 1 Clinical	Abl Bio Inc	Solid tumours	Details
CTX-8371	CTX-8371	Phase 1 Clinical	Compass Therapeutics LLC	Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Details
IBC-Ab002	IBC-Ab002	Phase 1 Clinical	ImmunoBrain Checkpoint Inc	Alzheimer Disease	Details
Pd-1-pik	Pd-1-pik	Phase 1 Clinical	Huashan Hospital Affiliated To Fudan University	Glioblastoma	Details
Reozalimab	IBI-318; LY-3434172; LY3434172	Phase 1 Clinical	Eli Lilly And Company	Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma	Details
VSV-02	VSV-02	Phase 1 Clinical	Joint Biosciences Ltd	Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours	Details
188Re-NM-01	188Re-NM-01	Phase 1 Clinical	Nanomab Technology Ltd	Lung Neoplasms	Details
68Ga-NOTA-WL12		Phase 1 Clinical	Beijing Cancer Hospital	Carcinoma, Non-Small-Cell Lung	Details
[18F]DK222	[18F]DK-222; [18F]DK222	Phase 1 Clinical	Sidney Kimmel Comprehensive Cancer Center	Carcinoma; Carcinoma, Non-Small-Cell Lung	Details
JSKN-027	JSKN027; JSKN-027	Phase 1 Clinical	Alphamab Oncology	Neoplasms; Solid tumours	Details
PF-08046037	PF-08046037; SGN-PDL1iT	Phase 1 Clinical	Pfizer Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck	Details
BMS-986238	BMS-986238	Phase 1 Clinical	Bristol-Myers Squibb Belgium Sa	Lymphoma; Solid tumours	Details
Naptumomab estafenatox/Durvalumab	NTX-352	Phase 1 Clinical	Neotx Therapeutics Ltd	Solid tumours	Details
DCR-PDL1	DCR-PDL1	Phase 1 Clinical	Dicerna Pharmaceuticals Inc	Solid tumours	Details
XB-628	XB628	Phase 1 Clinical	Exelixis Inc	Neoplasms; Solid tumours	Details
BHP-01	BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T	Phase 1 Clinical	Chengdu Brilliant Pharmaceutical Co Ltd	Small Cell Lung Carcinoma	Details
JSKN-022	JSKN022; JSKN-022	Phase 1 Clinical	Alphamab Oncology	Neoplasms; Solid tumours	Details
LW-347	LW-347	Phase 1 Clinical	Shanghai Longwood Biopharmaceuticals Co Ltd	Neoplasms	Details
A-337 (Klus Pharma)	A337 (Klus Pharma); A-337 (Klus Pharma)	Phase 1 Clinical	Klus Pharma Inc	Neoplasms	Details
PMI-06	PMI-06; PMI06; 18F-DK222; [18F]DK-222	Phase 1 Clinical	Precision Molecular Inc	Carcinoma, Non-Small-Cell Lung	Details
YL-222	YL222; YL-222	Phase 1 Clinical	MediLink Therapeutics Co Ltd	Solid tumours	Details
BAT-7205	BAT7205; BAT-7205	Phase 1 Clinical	Bio-Thera Solutions Ltd	Neoplasm Metastasis; Solid tumours	Details
SM-2275	SM-2275; SM2275	Phase 1 Clinical	Zhuhai StarMab BioMed Technology Ltd	Solid tumours	Details
ND-021	ND-021; NM21-1480; CS-2006; CS2006	Phase 1 Clinical	Cstone Pharmaceuticals, Numab Therapeutics Ag	Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Details
MAX-001	MAX-001; MAX001	Phase 1 Clinical	Inflamax Pharmaceuticals (Guangzhou) Co Ltd	Solid tumours	Details
KM602	KM602; KM-602; XZP-KM602	Phase 1 Clinical	Xuanzhu (Shijiazhuang) Biotechnology Co Ltd	Solid tumours	Details
B-901	B-901; B901	Phase 1 Clinical	FutureGen Biopharm (Beijing) Co Ltd	Solid tumours	Details
Recombinant anti-PD-L1/TGF-β bifunctional fusion protein		Phase 1 Clinical	Hualan Genetic Engineering (Henan) Co Ltd	Solid tumours	Details
AUR-106	AUR-106	Phase 1 Clinical	Aurigene Discovery Technologies Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Stomach Neoplasms	Details
177Lu-RAD204	177Lu-anti-PD-L1 sdAb; RAD-204; 177Lu-RAD204	Phase 1 Clinical	Radiopharm Theranostics Ltd	Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Mismatch Repair Deficient Cancer; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Details
RAD-203	RAD-203	Phase 1 Clinical	Radiopharm Theranostics Ltd	Carcinoma, Non-Small-Cell Lung	Details
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University)		Phase 1 Clinical	Sichuan University	Ascites; Serositis	Details
Ori-Bs-001	Ori-Bs-001	Phase 1 Clinical	OriCell Therapeutics Co Ltd	Solid tumours	Details
HBM-9027	HBM-9027; HBM9027	Phase 1 Clinical	Harbour Biomed	Neoplasms; Solid tumours	Details
HS-10386	HS-10386	Phase 1 Clinical	Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd	Solid tumours	Details
QL-415	QL-415	Phase 1 Clinical	Qlsf Biotherapeutics Inc	Neoplasms	Details
ASC-61	ASC-61	Phase 1 Clinical	Ascletis Pharma Inc	Neoplasms; Solid tumours	Details
BPI-371153	BPI-371153	Phase 1 Clinical	Betta Pharmaceuticals Co Ltd	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours	Details
CS-23546	CS-23546; CS23546	Phase 1 Clinical	Shenzhen Chipscreen Biosciences Co Ltd	Immune System Diseases; Neoplasms	Details
SG-1408	SG-1408; SG1408	Phase 1 Clinical	Hangzhou Shangjian Biotechnology Co Ltd	Solid tumours	Details
CHECKvacc	CF33-hNIS-antiPDL1	Phase 1 Clinical	City Of Hope National Medical Center, Imugene Ltd	Breast Neoplasms; Metastatic breast cancer; Triple Negative Breast Neoplasms	Details
Gallium [68Ga] Natan recombinant PD-L1 single domain antibody	SNA-002; 68Ga-NOTA-SNA002	Phase 1 Clinical	Smartnuclide Biopharma	Contrast agents; Neoplasms; Solid tumours	Details
SHS-009	SHS-009; SH009; SH-009	Phase 1 Clinical	Nanjing Sanhome Pharmaceutical Co Ltd	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
CN-202	CN-202	Phase 1 Clinical	Curon Biopharmaceutical Ltd	Hematologic Neoplasms; Solid tumours	Details
Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical)	BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1	Phase 1 Clinical	Wuhan Binhui Biotechnology Co Ltd	Melanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms	Details
FS222 mAb² (F-star Therapeutics)	FS-222	Phase 1 Clinical	F-star Beta Ltd	Neoplasm Metastasis; Neoplasms; Solid tumours	Details
IMM-2520	IMM-2520	Phase 1 Clinical		Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
TT-00420/Atezolizumab		Phase 1 Clinical	TransThera Sciences (Nanjing) Inc	Gastrointestinal Neoplasms	Details
PF-07257876		Phase 1 Clinical	Pfizer Inc	Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck	Details
AN-4005	AN-4005	Phase 1 Clinical	Hangzhou Adlai Nortye Biopharma Co Ltd	Lymphoma; Neoplasms; Solid tumours	Details
BR-102	BR102	Phase 1 Clinical	Zhejiang BioRay Biopharmaceuticals Co Ltd	Neoplasms; Solid tumours	Details
TST-005	TST-005; TST005	Phase 1 Clinical	Suzhou Transcenta Therapeutics Co Ltd	Neoplasms; Papillomavirus Infections; Solid tumours	Details
GS-19	GT-90008; GS-19; GS-19-PLB-1C	Phase 1 Clinical	Gensun Biopharma Inc	Solid tumours	Details
Ragistomig	ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B	Phase 1 Clinical	I-Mab Biopharma Co Ltd	Solid tumours	Details
CCX-559	CCX-559	Phase 1 Clinical	Chemocentryx Inc	Neoplasms; Solid tumours	Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University)		Phase 1 Clinical	Sichuan University	Peritoneal Neoplasms; Pleural Effusion, Malignant	Details
QLS31901	QLS-31901; QLS31901	Phase 1 Clinical	Qilu Pharmaceutical Co Ltd	Neoplasms	Details
IMM2505	IMM2505; IMM-2505	Phase 1 Clinical	SunHo (China) BioPharmaceutical Co Ltd	Solid tumours	Details
SKB-337	SKB337; A-337; SKB-337	Phase 1 Clinical	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Solid tumours	Details
GNC-039	GNC-039	Phase 1 Clinical	Sichuan Baili Pharmaceutical Co Ltd	Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours	Details
IBI-323(Innovent Biologics)	IBI-323	Phase 1 Clinical		Neoplasms; Solid tumours	Details
BJ-005	BJ-005	Phase 1 Clinical	Boji Biomedical Technology (Hangzhou) Co Ltd	Lymphoma; Solid tumours	Details
Garivulimab	BGB-A333	Phase 1 Clinical	BeOne Medicines Ltd	Neoplasms; Solid tumours	Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu)		Phase 1 Clinical	Jiangsu Huaiyu Pharmaceutical Co Ltd	Solid tumours	Details
Durvalumab/Selumetinib sulfate		Phase 1 Clinical	Astrazeneca Plc	Neoplasms	Details
18F-BMS-986192	BMS-986192-[18F]	Clinical	Bristol-Myers Squibb Company	Neoplasms	Details
68Ga-THP-APN09		Clinical	Beijing Cancer Hospital	Lung Neoplasms	Details
[68Ga]Ga-NOTA-RW102		Clinical	Huashan Hospital	Carcinoma, Non-Small-Cell Lung	Details
18F-WL12	18F-WL12; 18F-WL-12	Clinical	Beijing Cancer Hospital	Lung Neoplasms	Details
68Ga-WL12	[68Ga]WL12; 68Ga-WL12; 68Ga-WL-12	Clinical	Beijing Cancer Hospital	Lung Neoplasms	Details
CTB-1	CTB-1	Clinical	GTS Biotech LLC	Neoplasms	Details
89Zr-KN035（Wuxi No. 4 People's Hospital）		Clinical	Wuxi No. 4 People	Solid tumours	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indication	Clinical Trial
Socazolimab	ZKAB001; STI-A1014; STIA-1014; ZKAB-001; STI-1014	Approved	Sorrento Therapeutics Inc, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd	善克钰	Mainland China	Uterine Cervical Neoplasms	Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd	2023-12-19	Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Osteosarcoma; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms	Details
Envafolimab	KN-035; ASC-22	Approved	3d Medicines (Sichuan) Co Ltd, Suzhou Alphamab Co Ltd	ENWEIDA, 恩维达	Mainland China	Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer	3d Medicines (Sichuan) Co Ltd	2021-11-25	Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Dermatofibrosarcoma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Hepatitis B, Chronic; HIV Infections; Liver Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Sarcoma; Sepsis; Shock, Septic; Solid tumours; Stomach Neoplasms	Details
Retlirafusp alfa	SHR-1701	Approved	Jiangsu Hengrui Medicine Co Ltd	艾泽利	Mainland China	Stomach Neoplasms; Esophageal Neoplasms	Suzhou Suncadia Biopharmaceuticals Co Ltd	2026-01-07	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphangioma, Cystic; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms	Details
Atezolizumab	RG-7446-42; RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A	Approved	Genentech Inc	泰圣奇, Tecentriq, 泰善可	United States	Carcinoma, Non-Small-Cell Lung	Genentech Inc	2016-05-18	Anus Neoplasms; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chondrosarcoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Kidney Diseases; Kidney Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liposarcoma, Myxoid; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoproliferative Disorders; Melanoma; Metastatic breast cancer; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oropharyngeal Neoplasms;	Details
Avelumab	PF-06834635; MSB-0010718C	Approved	Merck Serono	Bavencio	United States	Carcinoma, Merkel Cell	Emd Serono Inc	2017-03-23	Adenocarcinoma; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Glioblastoma; Gonadal Disorders; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Meningeal Neoplasms; Meningioma; Mesothelioma; Microsatellite Instability; Microsatellite instability-high cancer; Multiple Myeloma; Mycosis Fungoides; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Papil	Details
Tagitanlimab	KL-A167; A-167; HBM-9167	Approved	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	科泰莱	Mainland China	Nasopharyngeal Carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	2024-12-25	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
Adebrelimab	SHR-1316; HTI-1088; HTI-1316	Approved	Atridia Pty Ltd, Jiangsu Hengrui Medicine Co Ltd	艾瑞利	Mainland China	Small Cell Lung Carcinoma	Shanghai Suncadia Medicine Co Ltd	2023-02-28	Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Diseases; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	Details
Durvalumab	28X28X9-OKV (UNII code); MEDI-4736	Approved	Medimmune Llc	Imfinzi, 英飞凡	United States	Carcinoma, Non-Small-Cell Lung	Astrazeneca Uk Ltd	2017-05-01	Adenocarcinoma; Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Hydronephrosis; Kidney Neoplasms; Laryngeal Diseases; Laryngopharyngitis; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peri	Details
Cosibelimab	TG-1501; CK-301	Approved	Dana-Farber Cancer Institute	UNLOXCY, UNLOXCIT, Unloxcyt	United States	Carcinoma, Squamous Cell	Checkpoint Therapeutics Inc	2024-12-13	Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma	Details
Sugemalimab	CS-1001; WBP-3155	Approved	Cstone Pharmaceuticals (Suzhou) Co Ltd	择捷美, Cejemly, ZEJIEMEI	Mainland China	Carcinoma, Non-Small-Cell Lung	Cstone Pharmaceuticals (Suzhou) Co Ltd	2021-12-20	Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms	Details
Atezolizumab/Hyaluronidase		Approved	Genentech Inc	TECENTRIQ HYBREZA	United States	Sarcoma, Alveolar Soft Part; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma	Genentech Inc	2024-09-12	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma, Alveolar Soft Part; Small Cell Lung Carcinoma	Details
Benmelstobart	CBT-502; APL-502; TQ-B2450; TQB2450; TQB-2450	Approved	Apollomics Inc	安得卫	Mainland China	Small Cell Lung Carcinoma	Sino Biopharmaceutical Ltd	2024-04-30	Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Digestive System Diseases; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal Diseases; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Hepatitis B, Chronic; Hodgkin Disease; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Ovarian Neoplasms; Peritoneal Neoplasms; Primary mediastinal B cell lymphoma; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details

Customer Reviews

C***z2025-04-30
PE-Labeled Human PD-L1 / B7-H1 (19-238) Protein, His TagStar Staining
We are always very satisfied with the reagents ordered from ACRO!
A***n2024-10-18
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
We order at Acrobiosystems for ELISA/ECL reagents. Up to now, we are happy with their products (quality) and the support they provide to us. It is quick to have a quote and very fast shipment.
Y***n2023-04-22
Human PD-L1 / B7-H1 Protein, Fc Tag, low endotoxin (MALS verified)
The delivery is so fast and so good.we received the package in two days.The products are very good in quality.And the price is reasonable.Those are quality products.We trust them. They are useful in our experiments. The results come from the products are stable and reliable.So if someone wants to get something like this, they can buy the products of the company.You will be not disappointed.They are really good!
1***32022-08-10
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
This is the third time we’ve purchased this antigen with good batch-to-batch stability and high experimental reproducibility. Both of our ELISA assays and activity experiments are proceeding smoothly and I hope the experiment goes well for the antibody screening as well! :)
A***i2022-06-29
Human PD-L1 / B7-H1 (19-134) Protein, His Tag (recommended for biopanning) (MALS verified)
In the past ACRO PDL1 antigen was used for the purposes of clone selection to find PDL1 binders. This lead to successful discovery of candidates for PDL1 binding. Now our protein production department uses this antigen for the purpose of QC of PDL1 binders. A wide range of QC experiments are performed using PDL1 antigen, this includes ELISA and SPR. All data using PDL1 antigen gives us consistent and reproducible results. In our experience we have never had any quality issues with this antigen from ACRO. It is a high quality produced and highly recommended.
Z***N2022-02-09
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
Using the PDL1 protein provided by Acro Biosystems, I am trying to screen for aptamers that can specifically bind to PDL1 and further use that aptamer for personalized cancer immunotherapy. Though the work is ongoing, I am impressed by the quality of the product and services offered by Acro Biosystems. Will share more about our work afterwards. If you plan to try PDL1 protein for your research, I will definitely recommend this one.
1***82019-09-27
Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
Acro's product quality control has always been very good. We used this protein for animal immunization and obtained a high serum titer. We stored the remaining product under 4 degrees. Over a month later, we used it for ELISA detection and the bioactivity was still pretty good.
1***22019-10-12
Human PD-L1 / B7-H1 Protein, Fc Tag, low endotoxin (MALS verified)
I used this protein for ELISA experiments. I coated it in a well plate, and then incubated it with the screened antibody molecules. I could get good binding data, and the repeatability and stability are good as well.
1***22019-10-12
Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
I purchased this protein for ELISA experiment. I coated CD80 protein into the well plate, and then mixed the antibody molecule and the biotin-PDL1 protein for a blocking assay. I could obtain ideal data.
1***62019-10-23
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
The PDL1 antigen was bought back for biological activity tests, including Elisa, etc. After the purchase, I also performed key replacement. The antigen has better purity and is more effective than similar antigens from other companies.
1***62019-10-18
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
The purity of human PD-L1 was tested via SEC-HPLC and it was high. I purchased this product for the QC. Everything looks great. The quality of the products is excellent, and product delivery was fast. We use a lot of Acro’s products, the purity is very good.
1***32019-10-11
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
The PDL1 antigen was purchased for phage display. I performed biotin labeling and got a good number of positive clones. Compared with similar products, I could only obtain about dozen positive clones on 96-well plates using antigen products from other vendors. By using this antigen from ACRO, I could pick out more than thirty clones. The result was very good. In addition, I also used this product for bioactivity testing, including Elisa, WB, Biacore, etc., and the result was also significantly improved compared products from other vendors.
1***62019-10-10
Human PD-L1 / B7-H1 Protein, His Tag, low endotoxin (Mass Spec & MALS & BLI verified)
The purity of human PD-L1 is very high, which is detected by SEC-HPLC. Besides, the biotin-labeled proteins with avitag are also easy to use for measuring KD. I purchase their products often.